Easton Pharmaceuticals, Inc. engages in the design, development, and marketing of drugs, therapeutic, and cosmetic healthcare products. The company is headquartered in Toronto, Ontario. The company went IPO on 2000-09-29. The firm has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The firm owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The firm's products are in various stages of commercialization. The firm's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.
EAPH stock price ended at $0 on 星期一, after rising NaN%
On the latest trading day Feb 09, 2026, the stock price of EAPH rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 63.3K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 73.3K shares were traded, equating to a market value of approximately --.